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The search for the genetic variations underlying all human phenotypes is in its infancy but must be one of the long term goals of the scientific
community. There is evidence that most, if not all human phenotypes, including illnesses are influenced by the genetic makeup of the individual.
There are an estimated 11 million human genetic polymorphisms with a minor allele frequency >1% and possibly many times that number of rare
sequence variants. The proportion of these sequence variants which have any functional effect is unknown but it is likely that the majority of those
which influence illness lie outside of the amino acid coding regions of genes, and affect the regulation of gene expression—these are called rSNPs.
Recent research suggests that about 50% of genes have one or more common rSNPs associated with them and probably most if not all genes have
an rSNP within the human population. In the long term, determining which polymorphisms are potentially functional must be done bio-
informatically using algorithms based upon experimental data. However, at the current time, the limited data that has been obtained does not allow
the creation of such an algorithm. In vitro studies suggest that a large proportion of rSNPs lie within the core and proximal promoter regions of
genes but it is not clear how the majority of these influence transcription, as they do not appear to be within any known transcription factor binding
sites. However, promoter regions possess a number of sequence-dependent characteristics which make them distinct from the rest of the genome,
namely stability, curvature and flexibility. Subtle changes to these features may underlie the mechanisms by which many polymorphisms exert
their function.
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The identification of sequence variation or mutations which
cause mendelian or single gene disorders has been ongoing
since the early 1980’s and the pace of discovery has accelerated
rapidly. At the same time, the recognition of the role played by
genetic variation in a range of phenotypes and disease has also
grown. While the number of illnesses known to have a genetic
component runs into the thousands, the influence of genetic
variance on many other phenotypes has been demonstrated by
twin studies or similar approaches [1].
It is now becoming clear that the pathogenesis or etiology of
the vast majority of human diseases is influenced to some
extent by genetic variation. This includes illness whose primary0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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genetic variance alters the susceptibility to both bacterial
infections such as malaria [2,3] and viral diseases such as HIV
[3], while autoimmune disease such as multiple sclerosis are
also associated with specific genotypes [4]. In addition, an
individual’s susceptibility to the pathogenic effects of a range
of exogenous toxins is strongly influenced by the activity of
phase 1 and phase 2 breakdown enzymes which vary due to a
number of genetic polymorphisms [5]. Even conditions which
are strongly influenced by sociological forces such as eating
disorders, including anorexia and obesity, are thought to have a
genetic component to their pathology [6].
2. Why it is important to find functional SNPs
The number of protein encoding genes in the human
genome has been found to be unexpectedly low; in the region
of 20–25,000, while complexity and variation in mechanismsta 1762 (2006) 17 – 28
http://www
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This has led to the hypothesis that variations in the expression
of genes, rather than the expression of different genes, underlie
the complexity and variation of human phenotypes; thus
regulatory polymorphisms may be the main source of human
variation [1,7,8].
In recent years, the focus of molecular genetic research has
moved from rare diseases with simple patterns of inheritance to
the common diseases of multi-factorial origins in which the
genetic component consists of multiple genes, each of which
individually makes a small to moderate contribution to disease
risk. These so-called Fcomplex_ diseases are of much greater
importance to human health than the simple genetic disorders
in that together they are responsible for most human morbidity
and mortality (mental illness, cardiovascular disease, asthma,
diabetes, dementia etc) and are probably involved in a variety
of important animal phenotypes also [9,10].
Understanding the fundamental genetic mechanisms of such
diseases is therefore a priority in medical research [11,12].
Central to translating the genetic findings to the clinic is
identifying the pathogenic alleles. Only by identifying the
pathogenic alleles can we make accurate predictions about the
nature of their pathogenic function and most importantly
generate accurate models of the disease in vitro and in vivo
which are key steps in translating the genetic findings into new
therapeutic interventions. Moreover, identifying the suscepti-
bility allele maximises the translational power of genetics for
diagnostics because without it, we cannot determining the true
magnitude of the genetic effect. The susceptibility SNP itself
provides optimal power for gene based risk prediction in
different populations and for examination of specific pheno-
typic correlations. The use of the susceptibility allele is also
most potent for downstream studies of gene–gene and gene–
environment interactions. Understanding the latter is likely in
particular to be of immense clinical value, the environment
being generally more modifiable than the genome. In relation
to gene regulation, the susceptibility SNP is the rSNP, which
has a functional effect on expression and all rSNPs are
potentially susceptibility SNPs for phenotypes, including
diseases.
Although mapping disease genes for complex diseases is
difficult, an increasing number of susceptibility genes have
now been identified as a result of the availability of full
genome sequence, dense marker maps and high throughput
genotyping platforms. However, in most cases, the true
susceptibility variant or variants remain unknown and extreme-
ly difficult to identify. There are several reasons for this
including weak correlations between variant and phenotype as
a result of weak genetic effects, allelic and locus heterogeneity,
and difficulties in phenotype definition [13]. However, one of
the most important issues arises from the existence of linkage
disequilibrium (LD) between DNA variants. Extensive LD
makes the task of gene identification easier, but it also means
that it is often difficult or even impossible to distinguish on
statistical grounds between the susceptibility variant and those
variants simply in LD with it [8,14–16]. Moreover, it is also
difficult to make such a distinction based upon the likelyfunctional properties of the SNP. Again, this contrasts with
simple genetic disorders where disease mutations are often
readily identifiable because of our knowledge of the rules of
gene translation and where the mutation landscape is domi-
nated by mis-sense and nonsense mutations. However, for
complex diseases, it is now generally accepted that variants
which exert their effects on disease susceptibility generally do
so through more subtle mechanisms, of which altering gene
expression is a major player [1,7,8,11,12]. These regulatory
polymorphisms or rSNPs are unfortunately not easily separated
from non-functional variants based upon any predictable
characteristics. Moreover, since there are an estimated 11
million human SNPs with a minor allele frequency >1% [16] as
well as innumerable rarer variants that might in principle
cumulatively make an important contribution to disease [17],
there are no experimental procedures in use, or on the horizon,
which could functionally distinguish between those of func-
tional importance and those that are not. The sheer magnitude
of the task suggests that wet-experimental procedures are
unlikely to solve the problem, and that instead, an iterative
combination of descriptive wet laboratory data acquisition, the
development subsequently of bioinformatics predictions, and
wet laboratory testing of those bioinformatics prediction will be
required. The successful development of such a set of
bioinformatics tools is likely to prove crucial in identifying
susceptibility variants [11,12] by positional cloning either after
linkage or after whole genome approaches to genetic associ-
ation, the two approaches that are most powerful for those
diseases where our knowledge of pathophysiology is weak and
which stand most to gain from non-hypothesis based genetic
approaches.
3. What variations in genes are involved?
Genetic sequence variants which involve the substitution or
deletion of a single or small number of bases are frequently
referred to as simple nucleotide polymorphisms, or SNPs. It is
convenient to use this term regardless of the frequency with
which the SNP occurs in any population or the number of bases
involved.
In principal, SNPs in protein encoding genes can influence a
phenotype in two ways, either by changing the quality or
quantity of the encoded protein. Those changes are transmitted
from the gene to the protein via mRNA; the former is
represented by changes to the sequence of the encoding
mRNA whilst the latter is represented by changes to the
abundance of the encoding mRNA, or in the rate of translation
of the mRNA into protein. Changes to the activity, processing,
trafficking, etc. of the protein are controlled by other proteins,
which in turn are regulated as above.
Non-synonymous SNPs are those which result in the change
of a codon which gives rise to a different amino acid; however,
SNPs which alter splicing can also lead to changes in protein
sequence. Splicing is controlled by the splice acceptor, donor
and branch site but also by exonic splicing enhancers, which
are involved in the recognition of exons by the splicing protein.
Changes to any of these sequences can give rise to altered
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protein; up to 25% of alternative transcripts have premature
stop codons leading to nonsense mediated decay [18].
Alternative splicing can occur, giving rise to alternative first
exons and therefore alternative promoters. Different promoters
may be used to confer tissue, developmental or state specificity
as well as giving rise to different coding sequences [18].
Clearly, any SNP in an alternative promoter will only exert its
effect when that promoter is used, and as such may exert a
tissue, developmental or state effect. For example, a SNP in
one promoter of the prolactin gene causes changes to gene
expression in lymphocytes but not the pituitary, and may be
associated with systemic lupus erythematosus [19].
The regulation of gene expression is complex, as all stages
of the process are under some form of control. The principal
control stages are at the levels of transcription, mRNA stability
and translation. Any method which is based on measuring the
relative abundance of mRNA which encodes specific proteins
will detect changes to transcription and mRNA stability, but
not translation. The control of translation is primarily modu-
lated by sequences within the 3V and 5V untranslated regions
(3VUTR and 5VUTR). This control has been reviewed previ-
ously [20] and the effect of sequence variants has been
described [21,22] and illnesses such as myotonic dystrophy
and a-thalassemia can be caused by such mutations [22].
The stability, or turnover, of mRNA is a tightly regulated
process dependent on specific cis-acting sequences and trans-
acting factors [23]. The minimal recognition sequence for RNA
destabilising enzymes is UUAUUUAUU which appears in the
3VUTR of many genes [24]. However, many functional
recognition elements do not contain this sequence or variants
of it, and alone it is not sufficient for binding of the proteins
involved in RNA degradation; several copies of the sequence
element are required and proteins recognise and bind to a
combination of primary and secondary structure elements
(stem–loops) formed in the mRNA [23].
Several diseases are known to be caused by deletion of part
of the recognition element [22] or by alternative splicing (e.g.,
[25,26] and other complex diseases may be influenced by SNPs
in these elements; for example two SNPs in the 3VUTR of
CRTH2 are associated with asthma and the associated
haplotype has a higher level of mRNA expression caused by
an increase in mRNA stability [27]. The regulation of a number
of genes is known to be affected by 3VUTR SNPs (for example:
[5,28–30].
However, there are a limited number of SNPs known to
exert an effect on mRNA stability or translation. In comparison
there are well over a hundred sequence variants known to affect
transcription in vitro [31,32] and the presence of many more
has be detected using in vivo methods [33–38]. Evidence
suggests that there are many thousands more waiting to be
discovered.
4. Allelic expression analysis
Factors which affect gene expression can be categorised as
either trans or cis-acting phenomena. Cis-acting effects arethose which act only on a single gene on the same
chromosome, for example a SNP in a regulatory element
(rSNP) or parental imprinting of a gene. Trans-acting
influences are all other effects. Examples are: changes to one
gene (regulatory or amino acid sequence) which in turn
influences the expression of a second gene; and any effect
resulting from a non-genetic factor such as drugs or hormones.
From the perspective of any given gene, cis effects are copy
specific while trans effects influence both parental copies
equally (unless the trans-effect is overridden by a cis-acting
event such a polymorphism that renders one copy more or less
sensitive to the trans-acting influence, that is, a gene–
environment interaction). In practice, this makes identifying
the presence of rSNPs or cis-effects harder than identifying
trans-effects.
For example, the use of microarrays allows a comparison of
the relative abundance of the mRNAs which encode the
majority of genes in the genome, variations of which are
primarily due to differences in the rate of transcription of these
genes between individuals. Comparisons between groups of
individuals with an illness and a control group typically
identifies hundreds of differentially regulated genes. However,
these differences are probably mainly due to environmental or
state effects such as illness, nutritional state, age, time of day of
sampling, and so on; in other words trans-effects. They do not
reflect genetic sequence differences (cis-effects) in the control
of those genes, or indeed of any other ‘‘upstream’’ genes.
A report by Morley et al. illustrates several of the points
above [8]. The variation in expression of ¨8500 genes in
CEPH lymphoblast cell lines was studied using microarrays.
Using the known genotypes of these samples Morley et al.
(2005) were able to carry out in silico linkage analysis. They
found that the basal expression of up to 1000 genes appeared to
be controlled by genetic effects, and of 142 studied in more
detail, 20% appeared to have a cis-acting transcriptional
regulator. However, they were not able to indict any specific
SNPs as being rSNPs.
Recently, we [33] and others [34–38] have developed
indirect methods for detecting the presence of even distal cis-
acting sequence variants that affect the expression of an
assayed gene independently of trans effects. By measuring
the relative expression of the paternal and maternal copies of
autosomal genes we can selectively detect cis-effects, hetero-
zygosity for which is indicated by deviation of the ratio of
expression of parental copies from unity, while controlling
precisely for trans effects.
The detection of allele-specific gene expression in a single
individual relies on the ability to distinguish the gene product
of one parental chromosome from that of the other, and then
to quantitate the relative amounts of each gene product that is
produced. Three studies have been carried out using the
method of single nucleotide primer extension [39]. A
transcribed polymorphism is used as a marker to distinguish
between the mRNA products of the parental chromosomes.
The relative abundance of each allele from a heterozygous
individual is then quantitated using RT-PCR and primer
extension with radio labelled [39] or fluorescent nucleotides
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samples and have been subject to the same environmental
influences including genetic trans-acting factors and experi-
mental insults including mRNA degradation. In the absence
of either cis-acting sequence variation or epigenetic effects
affecting expression of the target mRNA, each chromosome
should be equally expressed regardless of the absolute level
of gene expression. The ratio of the abundance of each allele
is therefore expected to be ¨1. In samples that are
heterozygous for a cis-acting regulatory variant or epigenetic
modification, mRNA originating from one chromosome will
be expressed at a higher level than that from its sister
chromosome and this is detected by changes in the ratio of
abundance of each mRNA allele.
In the first reported survey of allelic discrimination, this
method [39] was used to study 13 genes in 96 CEPH
lymphoblast samples and variable allelic ratios were found in
6 genes [34]. The variations were found in 18–39% of
individuals and the magnitude of variation ranged from 1.3-
to 4.3-fold, although only 1 gene gave variations above a factor
of 1.9. Of importance, the results from three families were
consistent with inheritance of the variations.
A second survey used a similar method to that above to
study an additional 15 genes [33]. Of importance, the mRNA
was extracted from 50 post mortem human brain cortex
samples, eliminating the possibility of artefacts caused by the
immortalization of lymphocytes. Seven genes displayed allelic
expression differences of over 1.2-fold, the largest being 1.7.
For the variably expressed genes, between 5% and 66% of
individuals showed differences.
A third survey again used a similar method to that above to
study 129 genes in lymphoblast mRNA [38]. Of those, 23
genes showed relative allelic expression of 1.7-fold or greater
(the chosen cut off point), the largest difference, not including
imprinted genes, being 9-fold. For the variably expressed
genes, between 11% and 100% of individuals showed
differences. At least one of these genes was also shown to
have allele-specific expression in adipose tissue.
The similarity in these three studies of the magnitude of
changes and the proportion of both the genes and individuals
showing variation suggests that the source of the tissue is
not critical, although clearly any state effects related to
illness and drug treatment could only be detected in primary
tissue samples.
A higher through-put method, allele-specific micro-arrays
has been used to measure the levels of mRNAs [37]. 602 genes
were studied and 326 (54%) showed a greater than 2-fold
difference, while 170 (28%) showed a greater than 4-fold
difference. However, this method only allowed the identifica-
tion of 2-fold or greater differences in allelic expression. The
work was carried out using liver and kidney from a relatively
small number of human fetuses. For each gene, no more than 5
heterozygotes were studied and for over 220 (68%) of the
genes only 1 or 2 heterozygotes were available. Thus, they had
very low power to detect allelic differences and the rate of
differences found is therefore far higher than that found by
others above [33,34,38] and it is not clear whether the higherfrequency and magnitude of variation stem from the tissue
differences or experimental limitations.
An alternative approach to measure allele-specific transcrip-
tion has been developed which measures differential initiation
of transcription from genomic DNA using a SNP in the
promoter region as a marker [36]. An antibody specific to Ser5
phosphorylated DNA pol II is added to the samples and
crosslinked to the DNA by formaldehyde treatment. The
chromatin is fragmented and the resulting protein bound
chromatin is immunoprecipitated (ChIP). The relative amount
of each immunoprecipitated allele is measured using PCR and
primer extension. Despite the power of this method, only a
small number of genes have been studied this way [36,40–42].
While the above experiments do not allow an exact
determination of the proportion of genes which contain a
regulatory polymorphism (rSNP) in any population, what can
be concluded is that in a small population of less than 100
individuals at least 50% of the genes have an rSNP which alters
transcription by 20% or more. This is almost certainly an
underestimate as a variety of tissue-specific effects would not
be seen in a limited number of tissues and many state-specific
effects may not be found in such a small population. In
addition, as more than half of all sequence variants are rare
(minor allele frequency; MAF <1%) then in a small population
as above only about half of all SNPs present in a large
population would be found. These all suggest that given a large
enough population that for the vast majority of genes one or
more individuals will carry an rSNP.
However, these approaches, based upon allele-specific
quantitation of gene expression, have major limitations. Of
these, the most important is that they do not identify the
specific regulatory variant or variants responsible for altered
allelic expression, although as we have shown, in some
instances functional haplotypes can be identified [43–45].
However, even where this is possible, it is still necessary to use
an in vitro method such as a reporter gene assay in order to
implicate specific cis-acting polymorphisms as causal for
altered regulatory function. To achieve this, specific poly-
morphisms in specific regulatory elements have to be identified
and isolated.
A recent review describes various in vitro methods which
can be used to identify or validate regulatory SNPs [46]. One of
the methods which has not been widely used for this purpose
but which has great potential is the electrophoretic mobility
shift assay (EMSA). Many proteins involved in regulation of
gene transcription bind directly to specific DNA sequences in
order to exert their effect. Historically, many such DNA
sequences have been identified using EMSA. Double stranded
DNA of the sequence to be studied (which may be synthetic
oligonucleotides or short-cloned strands of DNA) is tagged
with a radioactive or fluorescent label and incubated with
cellular extracts to allow any DNA binding protein to bind if its
recognition sequence is present. The mixture is analysed on a
polyacrylamide gel and two bands should be present, one
representing the unbound DNA and a second band at higher
molecular weight which represents the DNA bound to a
protein. If two alleles of the same DNA segment are analysed
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protein can be assessed. A recent study by Mottagui-Tabar et
al. [47] has shown that this method could be used as the first
step in a procedure to find regulatory SNPs. They studied 10
SNPS which were located within putative transcription factor
binding sites (TFBS) and found that 7 of them did indeed give
differential protein binding. The effect of 4 of these 7 SNPs
was subsequently confirmed using a reporter gene assay.
Linnell et al. [48] have published a high throughput method
which gives similar information to a quantitative EMSA. By
using oligonucleotides on chips they cannot only quantitatively
determine the relative affinities of different alleles but by
comparing a large number of different sequences, they can go
some way to defining the influence of each sequence position
on the affinity of the TFBS for the respective transcription
factor (TF).
5. Reporter gene assays
The core promoter and proximal promoter regions contain
the elements that control the initiation of transcription and are,
therefore, a priori regions that plausibly harbour functionally
relevant polymorphisms with major effects on gene expression.
Also, at present, of the possible regulatory elements affecting
the transcription of a gene, only the core and proximal
promoter elements have highly specific predictable spatial
relationships with their respective genes, a relationship that we
[49] and others [50] have shown allows promoter sequences to
be identifiable in most cases, despite imperfections in gene
annotation, from public databases. Several in silico promoter
prediction methods have been developed in the past but with
limited predictive performance due to the lack of any
consensus sequences or structural features which are both
promoter specific and found in all promoters [51]. More
recently a number of advances in bio-informatics have allowed
more accurate identification or promoters [52]: http://www.
rulai.cshl.edu/CSHLmpd2/; [53]: http://www.mgs2.bionet.
nsc.ru/argo/; [54] The newer approaches are based upon the
complete human genome sequence, comparison of with that of
other species, full length mRNA sequences and also machine
learning algorithms. This makes promoters the only regulatory
element that can at present be studied in a high-throughput
manner and also the obvious first place to look for functional
polymorphisms.
The methodology most widely used to study gene promoters
has been the reporter gene assay. In brief, this involves cloning
different alleles of the regulatory sequence being studied
(usually the promoter region) into a plasmid which contains
the coding sequence for a reporter protein which is easily
quantifiable, such as luciferase, in such a way that the relative
activity of the regulatory sequence can be determined by the
amount of the reporter protein which is produced following
transfection of the plasmid into cultured cells [55].
Other sequences, which contain regulatory elements can be
studied using reporter gene assays, if they can be identified,
but the size of the region which may contain rSNPs for a
gene, may be 100s of kb long. The size of sequence whichcan be studied is limited not only by the cloning technology,
but by the number of SNPs likely to be found in the
sequence. If there is more than one bp difference between two
sequences which are to be compared, any difference in
transcriptional activity cannot be assigned to a specific locus
unless all possible haplotype variants have been analysed, and
possible multiple effects and epistasis have been taken into
account. A second problem related to size are Taq DNA
polymerase induced base changes, the frequency of which
increases with size of the amplimer and very long sequences
are hard to copy with 100% fidelity.
Promoter–reporter gene assays have been used since the
early 1980s and a large number of promoter region SNPs
have been analysed [31]. Rockman and Wray [31] list
approximately 100 SNPs which have given positive results
in reporter gene assays [31]. However, as most SNPs to be
tested were pre-selected on the basis of having prior
probability or functionality, a true assessment of the propor-
tion of promoter SNPs which are functional could not be
carried out. In addition, differences in experimental technique
and thresholds used make the data less amenable to meta-
analysis than would be desired.
The author and colleagues have recently completed a large
scale project to identify functional promoter SNPs in a
systematic manner [32]. This project had the advantages over
a meta-analysis as described above:
& SNPs studies were all those found in a screening set of 32
chromosomes, with no pre-selection.
& The same techniques and procedures were used throughout,
including the use of the same cell lines.
& The same threshold for functionality was employed.
Approximately 1000 genes were selected either randomly,
by chromosome (Chr 21 and 22-selected as they were the
first 2 chromosomes to be sequenced allowing a large
proportion of the genes to have their promoters identified) or
by relevance to mental illness [32,56–62]. Using a screening
set of 16 individuals of diverse ethnic origin, to find SNPs in
the first 500 bp upstream of the reported start of
transcription, half of the genes analysed (341) had 1 or
more SNPs. We were able to clone and functionally analyse
247 of the genes using two different cell lines. We found
that 54 genes had promoter haplotypes which differed in
their ability to promote transcription by 50% or more. This
threshold was chosen as it is equivalent to the presence of a
third copy of the gene.
We demonstrated that 8.4% of naturally occurring sequence
variants in the first 500 bp 5V to the start of transcription
resulted in changes in transcriptional activity in vitro by over
1.5-fold [32,56]. From the perspective of the gene rather than
the polymorphism, even in our small sample set of 32
chromosomes, functional variants were detected in approxi-
mately 10% of the genes studied. Given our study focussed
only on one regulatory element, the promoter region, that we
only had 30% power to detect any given allele with a minor
frequency of 1%, and that our definition of a functional
Fig. 1. Percentage of all sequence variants that are functional in relation to the
distance from the transcription start site. Sequence variants found in gene
promoters with more than one matching locus in the human genome were
excluded. Reprinted with permission from [32].
Table 1
Correlation between tissue specificity and context of functional SNPs
Functionality In TF binding site Not in TF binding site
Both cell linesa 4 14
Cell line specific 6 5
Correlation between SNPs which exert a tissue-specific effect and whether o
not they fall within a known transcription factor binding site consensus
sequence (nucleotide sequence context). Eleven SNPs in promoters were
inactive in one cell line and are not included. Reprinted with permission from
[32].
a Includes SNPs which lead to a statistically significant activity between
alleles of 1.3 fold or greater, P=0.11, 2 tail (Fishers exact test).
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genes whose expression is influenced by promoter region
polymorphisms is much higher than this.
Forty SNPs were identified as having functionality inde-
pendently of other SNPs, 20 of these lay within 100 bp of the
TSS while another 10 lay within 100–200 bp of the TSS. The
non-functional SNPs were distributed evenly showing that the
position of functional SNPs is strongly biased towards the core
and proximal promoter as shown in Fig. 1.
This may be due to the fact that the RNA polymerase II
binding site and other TF binding sites are present in this
region of the promoter. However, an analysis of the sequences
within which the functional SNPs lie shows that the majority
do not appear to disrupt a known TF binding site. This is
unexpected as the core and proximal promoter regions are
probably the best studied regulatory regions of human genes
and the existence of a large number of unknown consensus
sequences which lie within this region seems unlikely. Indeed,
this has been demonstrated for sequence of eight base or less.
In a large survey of 13,000 human promoters, Fitzgerald et al.
(2004) determined the distribution of each of the 65,536
possible eight base DNA sequences which might act as
TFBSs [63]. They found statistically significant clustering of
seven known TFBS consensus sequences and a novel
sequence they named as Clus1. Each of these was mainly
found within 100 bp of the start of transcription. This
suggests that if unknown TFBSs in the core promoter region
are waiting to be discovered there must be a large number of
relatively rare consensus sequences, rather than a few
common ones. However, a more recent survey which studied
sequences of 6 to 18 bp by comparison with other species,
found 105 new motifs in human promoters, 85 of which were
9 or more bp long [64] and therefore would not have been
found by Fitgerald et al. [63]. It is not known if any TFs bind
to these sequences or if they have other roles in the regulation
of transcription.An additional finding was that 29 of the gene promoters
which contained a functional SNP were active in both cell
lines; 18 of these SNPs were functional in both cell lines while
11 were functional in only one cell line. Cell line specificity is
most likely due to the presence of a TFBS for a tissue-specific
TF. Interestingly, when SNPS with cell line specificity were
compared with those laying with TFBSs, a strong correlation
was observed (Table 1). This result therefore, is consistent with
the hypothesis that those functional sequence variants not in a
known TFBS may influence transcription by a mechanism
which is independent of the presence of transcription factors,
possibly related to some basic properties of the DNA itself.
Overall, our research and that of others has shown genes are
commonly influenced by cis-acting polymorphisms, and that as
we predicted, the promoter is a rich source of functional
variants.
However, there are a number of important questions which
stem from that work.
5.1. What is the relationship between in vitro results and the
situation in vivo?
Allelic expression assays are powerful in detecting the
presence of cis-acting effects. However, they have limited
utility in locating or identifying the source of the effect. For
this, the method of choice is the reporter gene assay. In a small
number of cases changes found in reporter gene assays have
been causally associated with a functional effect [1], but in the
overwhelming majority of cases there is no evidence that these
in vitro effects have any bearing on in vivo expression levels.
Reporter gene assays use only a limited amount of the genomic
DNA sequence associated with a gene and any effects
stemming from the sequence analysed may be abolished or
modulated by the effects of other sequence elsewhere in the
genome. In addition, the structure of the chromatin and the
effects of nucleosomes are not taken into account.
While it is not unreasonable to assume that reporter gene
assays are, in fact, relevant to in vivo expression, these
experiments are of such fundamental importance in the study of
gene expression that an investigation into the reliability and
validity of these assays is overdue. The obvious way to do this
would be by comparing data between reporter gene and allelic
expression assays. This is not as straight forward as it seems.
Given an mRNA sample from an individual who is heterozy-
gous for a promoter region SNP which is functional in an inr
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gene copies compares at the same time all sequence differences
in the gene region. Therefore, any difference in expression may
be related to any one of these. If a number of heterozygous and
homozygous samples are similarly analysed, in principal, if all
the heterozygotes give a difference in the same direction while
none of the homozygotes do, then this suggests that the SNP in
question is functional. However, it may be in linkage
disequilibrium with another functional SNP and in addition,
there may well be other functional SNPs which would give
apparent ‘‘false positives’’ and ‘‘false negatives’’, the latter
occurring when the effect of the target SNP is countered by
another functional SNP.
5.2. Does differential allelic expression lead to phenotypically
relevant changes?
In vivo analyses described above suggest that at least 50%
of genes show differential allelic expression. However,
although one haplotype of a gene may be expressed at a lower
level relative to another in individuals who are heterozygous
for that haplotype (confirming a cis-effect of that haplotype),
trans-acting homeostatic mechanisms might compensate for
this, resulting in unaltered total mRNA abundance. If this is the
case for any rSNP, it may have much less phenotypic impact
that might be presumed. The report by Morley et al. [8]
discussed above shows that the expression of many mRNAs is
influenced by genotype, but give no measure of the proportion
of rSNPs which do change total mRNA levels, nor do they
identify the rSNPs.
Similarly, Hirota et al. showed a correlation between the total
CYP3A4 mRNA level and allelic expression ratio, but did not
identify the rSNP(s) involved [65]. However, Liu et al. showed
by chromatin immunoprecipitation [36] that the GSTM3 gene
has a promoter rSNP (63A/C) which changes mRNA levels, as
shown by quantitative PCR [42]. It remains to be seen what
proportion of the rSNPs do actually exert a phenotypic effect,
and what the relative size of the two effects is.
5.3. What are the mechanisms by which promoter sequence
variants exert their effects on transcription
Several bio-informatic approaches to determining whether
or not a known SNP is functional have been reported, but all
depend on the SNPs disrupting or creating a TFBS [66–68].
Analysis of the sequence variants that influenced expression in
the reporter gene assay from the Cardiff promoter project [32]
revealed that most (¨70%) were not associated with known
consensus sequence motifs for TFBSs. This suggests that either
there are many as yet unknown consensus sequences relevant
to TF binding or that the majority of functional sequence
variants affect gene transcription in other ways. At a
fundamental level, the potential importance of determining
the answer to this question is equivalent to that of knowing the
role of codons in understanding the role of mis-sense and
nonsense mutations. Such an understanding is likely to be
decisive if we are to develop methods for predicting thefunctional properties of the vast majority of promoter regions
SNPs, and possibly SNPs in other regions adjacent to genes,
whose function is likely to remain un-assessed experimentally
given the laborious nature of doing so, at least with current
technology.
6. The human core promoter
The data presented in Buckland et al. (2005) [32] and Fig. 1,
as described above, suggests that the core and proximal
promoter regions are particularly sensitive to changes of a
single base pair. However, it is not clear why this should be so;
is it because there is a higher concentration of TFBSs or are
there other factors playing a role?
Text book descriptions of human core promoters, the
region which binds to the DNA polymerase II complex,
usually show a number of consensus sequences with the
implication that most if not all promoters contain these
elements, especially the TATA box. TATA-containing promo-
ters were first discovered in bacterial genomes and the TATA
box was thought to be the universal promoter element.
Human TATA-less promoters were discovered later and their
percentage in the total number of studied promoters has risen
steadily since: from 22% [69] to 36% [70] to 68% [71] and
most recently to 78% [72]. The TATA box is therefore present
in only a fifth of human promoters and in the others, RNA
Pol II must recognise some other factor(s) in order to
correctly initiate the start of transcription. Several other core
promoter elements are also known which fulfil this role: the
TFIIB recognition element (BRE), the downstream promoter
element (DPE) and the initiator (Inr). Each of these is only
found in a proportion of human promoters, the most common
element being the Inr which is present in approximately 50%
of promoters [72] but any combination of one, two or three of
the elements may be present, with or without a TATA box.
Each of these elements acts, either alone or with the others to
recruit TFIID to the polymerase initiation complex, by
binding to another transcription factor which in turns binds
TFIID, with the exception of Inr which binds TFIID directly.
Where the above elements are found, the spacing between
them can have a marked effect on transcription [72]. It is also
possible that sequences in the neighbourhood of these specific
elements are also be involved in the TFIID binding process.
However, approximately 25% of promoters have none of the
elements above and no other TFIID binding sequences are
known. This suggests that other factors are involved in TFIID
binding. One possibility is that other TFs bind to their
recognition elements and direct TFIID to the correct site.
Therefore, disruption of these TFBSs would affect transcrip-
tion. Another possibility is that the second order properties of
the promoter sequence can also play a role in transcription
initiation.
7. Transcription factor binding sites (TFBS)
At present, determining whether or not a base lies within the
DNA binding site for a protein transcription factor is fraught
Fig. 3. Flexible DNA allows transcription factor interaction. To allow two o
more protein–DNA complexes, which are not adjacent, to interact, the DNA
needs to bend around. The more flexible the DNA the greater the ease with
which the interaction can occur.
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consensus sequences are not yet known. However, even if we
assume all are known, determination of the presence of a TF
binding site and the effect a base change has on its affinity for
the TF is still problematic. TFBSs are not simply defined by a
specific sequence of nucleotides but rather by a set of such
sequences where the bases at several of the positions are
degenerate. In practice, there are very few human promoter
sequences that exactly match the consensus sequences. To
allow for this, sequences are interrogated for the presence of
putative TFBS using a matrix allowing for possible degeneracy
at all sites [63,73]. However, many weighting matrices are
derived from a limited number of known binding sites and the
effect of variation and the exact weight that should be accorded
for each of the nucleotides independently when predicting a
TFBS consensus sequence is not known for most such sites
[73,74]. Moreover, the affinity of the TF for its binding site is
not simply dictated by additive effects of changes at each site,
with nucleotide changes being interdependent in their effects
[74]. This means that in some cases at least, the effect of
changes to TF sites can only be determined experimentally for
each and every possible oligonucleotide sequence [74]. While
work to do this is being carried out [75], it will be some time
before the effect of all TFBS SNPs is known.
8. DNA structure
There have been few investigations into the relative
compositions of strong and weak eukaryotic promoters. The
presence of TFBSs clearly play a role, but several studies, both
experimental and computational, have shown that promoter
regions possess a number of sequence-dependent character-
istics which make them distinct from the rest of the genome;
stability, curvature and flexibility [76]. Curvature refers to the
shape of the DNA sequence and how it is bent. Sequence
flexibility refers to the ease with which the DNA can bend to
allow interactions of proteins bound to the DNA in different
places, or to avoid steric hindrance. Stability refers to the ease
with which the DNA can become single stranded to allow
transcription. While the majority of studies on the effects of
DNA structure on transcription have been carried out using
non-human DNA, there is no reason to believe that similarFig. 2. DNA melting following bending. When a transcription factor such as the
TATA binding protein binds to a DNA consensus sequence, it can cause the
DNA to bend and the strands to separate, as in (B) allowing transcription to
commence. If the formation of the protein–DNA complex does not result in
sufficient bending, strand separation does not occur and transcription is
inhibited as in (A).rmechanism do not apply to human DNA and this is supported
by some evidence [76].
Pedersen et al. studied the prokaryotic genome and found
that in practically all the investigated eubacterial and archaeal
genomes, there is a trend for promoter DNA to be more
curved, less flexible, and less stable than DNA in coding
regions and in intergenic DNA without promoters [77]. This
trend is present regardless of the absolute levels of the
structural parameters, and they suggest that this may be
related to the requirement for helix unwinding during
initiation of transcription.
8.1. DNA curvature
Curvature of the DNA duplex is central to how many TFs
exert their effects on gene expression. Depending on its
sequence, curvature can be an inherent property of a DNA
molecule or it can be induced by external factors, such as
protein binding [78]. It is known that curved DNA is often
located near transcriptional control regions [79,80].
The affinity of a transcription factor for its recognition
sequence is influenced by the average curvature of the
unbound DNA and there are different mechanisms leading
to this effect. One effect of curved DNA has been highlighted
[80]; intrinsically curved DNA is often found upstream of the
TATA box and it has been shown that this promotes an
association with nucleosomes which bends DNA towards the
major grove in the TATA region, exposing the minor grove
and this increases the rate of transcription. The curved DNA
need not itself be part of a TFBS to have this effect [80]. Kim
et al. [81] have shown that the insertion of one or more
copies of an intrinsically curved DNA sequence (A6CGTG)
into a minimal promoter upstream of a TATA box increases
transcription by 100-fold [81]. Change to this sequence which
abolished DNA bending reduced transcription by 70%. They
also showed that a sequence specific, rather than bending
specific protein binds to this sequence and promotes
transcription. We have found a similar sequence to that used
by Kim et al. [81] which occurs naturally in the promoter of
Fig. 4. DBA bending alleviates steric hindrance. Where two transcription factors are required to bind to their respective binding sites and the latter are close together,
they may only be able to bind if the DNA is bent to give more room. (A) Steric hindrance stops both proteins binding at the same time. (B) The curved DNA allows
more space for both proteins to bind at the same time.
Fig. 5. To allow one protein to bind to two stretches of DNA curved or flexible
sequences between the binding sites may be required as shown in B.
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retina. Interestingly, a promoter reporter gene clone with the
sequence A6GCTC, has twice the transcriptional activity of a
different allele having the sequence A6GATC [32]. Although
speculative, the AT dinucleotide is less flexible than the CT
dinucleotide [82] and this may influence the curvature of the
sequence.
A second effect of curved DNA stems from the fact that
binding of many TFs to DNA results in the bending of the
DNA. Unbound DNA with a curvature similar to that of the
DNA–TF protein complex has a lower free energy of DNA–
TF protein association (and therefore higher affinity for the
TF) than unbound DNA whose curvature is relatively
dissimilar, and which requires more distortion after TF
binding [83].
Experimental evidence suggest that following binding of the
RNA pol II to the promoter, the DNA strands separate and
wrap around the polymerase causing a sharp bend in the DNA
[84]. Also, the TATA binding protein (TBP) binds the minor
groove of the TATA recognition sequence and distorts the DNA
80- towards the major groove. DNA with a natural curvature
towards the major groove binds TBP with 100-fold greater
affinity than linear DNA and with 300-fold greater affinity than
DNA bent towards the minor groove [85]. An illustration of the
probable mechanism of this effect is shown in Fig. 2. Many
other transcription factors also facilitate the adoption of curved
conformations by DNA molecules [86,87]. Examples include
the cAMP receptor protein (CAP), purine repressor (PurR),
integration host factor (IHF) and the TATA-binding protein
(TBP) [78].
Another example of a TF that exerts its effect through
bending DNA is yeast MCM1. Mcm1 is a member of the
MADS-box family of TFs which are found in eukaryotes,
including yeast and mammals [88] and is involved in
regulating a range of genes. Factors which influence the
degree of DNA bending have been shown to be critical for
the activation of transcription following TF binding to the
consensus TFBS. A mutation in the MCM1 TF itself changes
its ability to bend DNA from 95- to 82- and this lowers
transcription by >10-fold [89,90]. Mutations in single bps of
the TFBS for MCM1 that are known to be involved in
bending, also decreases transcription by 4-fold [91,92].
However, although these substitutions have a large effect on
DNA bending and transcriptional activation by Mcm1, theyhave a relatively small effect on the DNA-binding affinity of
the protein.
Perhaps with respect to a human phenotype, one of the most
dramatic consequences of curvature and bending comes from a
mutation to the human male sex-determining factor SRY, a
mammalian TF. The High Mobility Group (HMG)-box domain
is approximately 80 residues in length and defines a
superfamily of architectural factors that play a central role in
mammalian gene regulation and organogenesis [93]. The
HMG-box domain of SRY binds to specific DNA sequences
in the minor groove, resulting in substantial DNA bending. A
number of mutations in the SRY gene which give rise to amino
acid changes in the DNA binding domain result in 46X,Y sex
reversal. One particular mutation has been shown to change the
DNA bend angle by 13-.
8.2. DNA flexibility
Flexibility of a DNAmolecule can be defined as the ease with
which the molecule can be made to curve in any direction, and
this is dependent on its sequence [94]. DNA is an inherently stiff
molecule; however, some DNA sequences, while being intrin-
sically straight, can readily undergo distortion. The flexibility of
DNA has been shown to be important in the formation of many
protein–DNA complexes [94] and increasing the flexibility may
allow greater binding of a TF or RNA pol II [95]. Examples of
this include TATA Binding Protein [85,96] and Catabolite
Activator Protein [97].
There are a number of ways in which flexibility of DNA
influences the way TF interact with DNA and modulate
transcription: DNA does not easily loop around to allow
upstream enhancer elements to become adjacent to the DNA
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stretches of flexible DNA facilitate this as shown in Fig. 3.
DNA sequences that are not intrinsically at the optimal
curvature for the binding of a TF but that can be easily
distorted by TF binding to it as a result of greater intrinsic
flexibility have lower free energy of DNA–TF association
than more rigid structures [83]. This kind of ‘‘indirect
recognition’’ may be more important in TF binding when
the complex requires large distortions in the DNA structure
[83]. Flexibility of DNA is important when two TFs bind to
TFBS which are close together, which is more likely to occur
in the proximal promoter where many TFBS are found. If the
DNA is rigid, both TFs may not be able to bind at the same
time due to steric hindrance (both proteins are trying to
occupy the same physical space at the same time). If the
DNA is flexible, it can bend to allow both TFs to bind at the
same time [87] as depicted in Fig. 4. Alternatively, DNA may
be required to bend to allow a TF to interact with two binding
sites as shown in Fig. 5.
8.3. DNA stability
DNA stability or its resistance to becoming single stranded
depends primarily on the sum of the interactions between the
constituent mono and dinucleotides. (For an oligonucleotide
this is referred to as the melt temperature.) Low stability aids
the melting of DNA by DNA polymerase and thus aids
transcription. Eukaryotic core and proximal promoter regions
are less stable than coding regions and often show a peak of
minimum stability between the 25 and 35 region,
probably due to the presence of the TATA box in some
promoters [76]. This can easily be determined bio-informa-
tically [99]. A simple analysis of the functional SNPs found
in the Cardiff Promoter Project found no resulting large
changes in DNA stability and approximately 50% of the
SNPs increased the stability (data not shown). Changes to
DNA stability does not therefore appear to be a major
mechanism by which promoter SNPs exert their effect.
9. Conclusions
The number of functional sequence variants in the human
genome, which are relevant to a phenotype, is unknown, but may
be many thousands. Identifying which of the many millions of
variants are functional is important for health and research, but
clearly each variant cannot be tested experimentally. What is
required is a bio-informatic method to assess the likelihood of
functionality based upon extensive experimental data. However,
at this time, the mechanism of action of few functional SNPs in
known and even those which appear to lie within a transcription
factor binding site may not in fact exert their effect by its
disruption. However, although structural factors such as DNA
curvature and flexibility are known to have a critical effect on
promoter function, little if any research has been carried out to
show if a single nucleotide polymorphism can change DNA
structure such as to have a functional effect. Nevertheless, in the
absence of competing explanations, my hypothesis, is thatsequence variants which lie outside of the consensus TF binding
sites may exert their effects by either altering the bending of the
DNA towards (or away from) its optimum configuration, or by
altering the flexibility of the DNA and changing its ability to
bend in the required way. The differences in level of
transcription that have been found to result from cis-acting
effects are mainly small. Thus, they may be caused by relatively
small changes to the conformation of DNA.References
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